Inventiva S.A./€IVA
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Inventiva S.A.
Inventiva S.A. is a clinical-stage biopharmaceutical company based in France, focused on developing oral small molecule therapies for the treatment of diseases with unmet medical needs, particularly in the areas of fibrosis, lysosomal storage disorders, and oncology. The company’s leading product candidate is lanifibranor, which is currently in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). Founded in 2012, Inventiva leverages its proprietary technology platform to identify and develop innovative compounds. The company's research and development operations are concentrated in Daix, France. Inventiva’s competitive strength lies in its robust pipeline and strategic collaborations with partners in the pharmaceutical industry. Sources:
1. https://inventivapharma.com/en/
2. https://ir.inventivapharma.com/
3. https://www.wallstreet-online.de/nachricht/14672309-inventiva-reports-financial-results-quarter-ended-september-30-2021
Ticker
€IVA
Sector
Primary listing
PAR
Industry
Biotechnology
Headquarters
Employees
116
Website
Inventiva S.A. Metrics
BasicAdvanced
€396M
-
-€3.08
0.61
-
Price and volume
Market cap
€396M
Beta
0.61
52-week high
€3.30
52-week low
€1.43
Average daily volume
29K
Financial strength
Current ratio
0.924
Quick ratio
0.903
Long term debt to equity
-95.626
Total debt to equity
-169.953
Interest coverage (TTM)
-1.13%
Profitability
EBITDA (TTM)
-96.695
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,251.10%
Operating margin (TTM)
-651.45%
Effective tax rate (TTM)
-0.17%
Revenue per employee (TTM)
€130,000
Management effectiveness
Return on assets (TTM)
-63.60%
Return on equity (TTM)
265.67%
Valuation
Price to revenue (TTM)
12.08
Price to book
-2.56
Price to tangible book (TTM)
-2.56
Price to free cash flow (TTM)
-1.974
Free cash flow yield (TTM)
-50.67%
Free cash flow per share (TTM)
-1.443
Growth
Revenue change (TTM)
-38.24%
Earnings per share change (TTM)
26.56%
3-year revenue growth (CAGR)
18.36%
10-year revenue growth (CAGR)
8.64%
3-year earnings per share growth (CAGR)
34.47%
10-year earnings per share growth (CAGR)
15.22%
Bulls say / Bears say
Inventiva secured €116 million in the second tranche of its structured financing, providing substantial capital to advance its Phase 3 NATiV3 MASH study. (globenewswire.com)
Analysts have become more bullish on Inventiva, with consensus estimates forecasting a 26% increase in revenues for 2025 and a significant reduction in loss per share. (simplywall.st)
The completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis marks a significant milestone, potentially leading to positive clinical outcomes. (stockanalysis.com)
Inventiva is expected to report a loss of 52 cents per share for the period ending September 30, 2024, indicating ongoing financial challenges. (tradingview.com)
The company's return on equity (ROE) stands at -1,642.75%, reflecting significant financial inefficiencies and potential concerns for investors. (finance.yahoo.com)
Despite securing substantial financing, the company's high debt levels and ongoing losses may pose risks to its financial stability and future growth prospects. (finance.yahoo.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Inventiva S.A. stock?
Inventiva S.A. (IVA) has a market cap of €396M as of August 01, 2025.
What is the P/E ratio for Inventiva S.A. stock?
The price to earnings (P/E) ratio for Inventiva S.A. (IVA) stock is 0 as of August 01, 2025.
Does Inventiva S.A. stock pay dividends?
No, Inventiva S.A. (IVA) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Inventiva S.A. dividend payment date?
Inventiva S.A. (IVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Inventiva S.A.?
Inventiva S.A. (IVA) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.